<i>TEAD4</i> is an Immune Regulating-Related Prognostic Biomarker for Bladder Cancer and Possesses Generalization Value in Pan-Cancer

Abstract

Recent studies have revealed the significant role of TEA domain family member 4 (<i>TEAD4</i>) in the development and progression of cancer. However, the potential role of <i>TEAD4</i> in the progression of bladder cancer (BC) remains to be explored. The aim of this study was to determine whether <i>TEAD4</i> could serve as a pan-cancer predictor of the prognosis for BC. Based on data mined from public databases, expression levels and clinical value of <i>TEAD4</i> were identified in BC and human pan-cancers. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis was performed to detect the <i>TEAD4</i> expression levels in BC cell lines. Gene Set Enrichment Analysis (GSEA) was carried out for functional analysis in BC, and the relationship between infiltrating immune cells and <i>TEAD4</i> expression was evaluated by the CIBERSORT algorithm in BC and pan-cancer data. <i>TEAD4</i> was overexpressed and associated with poor prognosis in BC and several types of cancers. GSEA and CIBERSORT algorithm suggested that various pathways including immune-related pathways were enriched in <i>TEAD4</i> high expression group and several immunocytes infiltrated were correlated with the expression of <i>TEAD4</i>. This study revealed <i>TEAD4</i> is an immune regulating-related predictor of prognosis for BC and has generalization value in pan-cancer.